A detailed history of Israel Englander (Millennium Management LLC) transactions in Macrogenics Inc stock. As of the latest transaction made, Millennium Management LLC holds 3,535,900 shares of MGNX stock, worth $11.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,535,900
Previous 3,312,672 6.74%
Holding current value
$11.4 Million
Previous $14.1 Million 17.37%
% of portfolio
0.01%
Previous 0.01%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.0 - $5.55 $669,684 - $1.24 Million
223,228 Added 6.74%
3,535,900 $11.6 Million
Q2 2024

Aug 14, 2024

BUY
$3.31 - $18.51 $10.7 Million - $59.6 Million
3,219,977 Added 3473.73%
3,312,672 $14.1 Million
Q1 2024

May 15, 2024

SELL
$9.77 - $21.47 $7.53 Million - $16.5 Million
-770,270 Reduced 89.26%
92,695 $1.36 Million
Q4 2023

Feb 14, 2024

SELL
$4.48 - $10.11 $679,096 - $1.53 Million
-151,584 Reduced 14.94%
862,965 $8.3 Million
Q2 2023

Aug 14, 2023

SELL
$4.62 - $7.54 $4.34 Million - $7.09 Million
-939,801 Reduced 48.09%
1,014,549 $5.43 Million
Q1 2023

May 15, 2023

SELL
$4.82 - $7.24 $4.11 Million - $6.17 Million
-852,885 Reduced 30.38%
1,954,350 $14 Million
Q4 2022

Feb 14, 2023

SELL
$3.34 - $6.98 $2.45 Million - $5.13 Million
-734,717 Reduced 20.74%
2,807,235 $18.8 Million
Q3 2022

Nov 14, 2022

BUY
$3.01 - $5.22 $2.81 Million - $4.87 Million
932,390 Added 35.73%
3,541,952 $12.3 Million
Q2 2022

Aug 15, 2022

BUY
$2.25 - $9.99 $2.46 Million - $10.9 Million
1,091,427 Added 71.89%
2,609,562 $7.7 Million
Q1 2022

May 16, 2022

BUY
$8.12 - $16.9 $3.97 Million - $8.26 Million
488,599 Added 47.46%
1,518,135 $13.4 Million
Q4 2021

Feb 14, 2022

BUY
$15.91 - $21.88 $8.23 Million - $11.3 Million
517,487 Added 101.06%
1,029,536 $16.5 Million
Q3 2021

Nov 15, 2021

BUY
$19.74 - $28.7 $586,672 - $852,964
29,720 Added 6.16%
512,049 $10.7 Million
Q2 2021

Aug 16, 2021

BUY
$20.49 - $35.63 $1.22 Million - $2.12 Million
59,627 Added 14.11%
482,329 $13 Million
Q1 2021

May 17, 2021

SELL
$18.99 - $33.2 $3 Million - $5.24 Million
-157,878 Reduced 27.19%
422,702 $13.5 Million
Q4 2020

Feb 16, 2021

SELL
$19.41 - $26.0 $1.76 Million - $2.36 Million
-90,746 Reduced 13.52%
580,580 $13.3 Million
Q3 2020

Nov 16, 2020

SELL
$24.69 - $31.6 $12.6 Million - $16.2 Million
-511,495 Reduced 43.24%
671,326 $16.9 Million
Q2 2020

Aug 14, 2020

SELL
$5.2 - $29.12 $2.32 Million - $13 Million
-446,198 Reduced 27.39%
1,182,821 $33 Million
Q1 2020

May 14, 2020

SELL
$4.28 - $12.11 $2.94 Million - $8.31 Million
-685,812 Reduced 29.63%
1,629,019 $9.48 Million
Q4 2019

Feb 14, 2020

SELL
$7.95 - $12.27 $6.59 Million - $10.2 Million
-829,086 Reduced 26.37%
2,314,831 $25.2 Million
Q3 2019

Nov 14, 2019

BUY
$12.44 - $17.48 $2.46 Million - $3.46 Million
197,867 Added 6.72%
3,143,917 $40.1 Million
Q2 2019

Aug 14, 2019

BUY
$14.51 - $19.71 $20.7 Million - $28.1 Million
1,423,910 Added 93.55%
2,946,050 $50 Million
Q1 2019

May 14, 2019

BUY
$11.11 - $25.6 $14 Million - $32.4 Million
1,264,460 Added 490.71%
1,522,140 $27.4 Million
Q4 2018

Feb 14, 2019

BUY
$11.75 - $21.42 $359,808 - $655,923
30,622 Added 13.49%
257,680 $3.27 Million
Q3 2018

Nov 14, 2018

SELL
$19.26 - $23.46 $3.82 Million - $4.65 Million
-198,241 Reduced 46.61%
227,058 $4.87 Million
Q2 2018

Aug 14, 2018

SELL
$19.78 - $24.67 $9.35 Million - $11.7 Million
-472,683 Reduced 52.64%
425,299 $8.78 Million
Q1 2018

May 15, 2018

BUY
$18.89 - $32.46 $7.85 Million - $13.5 Million
415,681 Added 86.19%
897,982 $22.6 Million
Q4 2017

Feb 14, 2018

BUY
$16.19 - $20.3 $6.72 Million - $8.43 Million
415,262 Added 619.43%
482,301 $9.16 Million
Q3 2017

Nov 14, 2017

BUY
$15.52 - $18.94 $1.04 Million - $1.27 Million
67,039
67,039 $1.24 Million

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $197M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.